PHARMA/BIO-TECH UPDATE: Biogen Partners with Sangamo
January 10th, 2014; Posted by: WeBleed staff
Biogen Idec announced yesterday via press release that they would have an exclusive worldwide collaboration and license agreement with Sangamo BioSciences to develop treatments for a group of inherited blood disorders in a deal for up to $320 million.
“Our collaboration with Sangamo is expected to help us expand our capabilities to develop treatments for people with serious, inherited hematologic conditions,” said Douglas E. Williams, Ph.D., Biogen Idec’s executive vice president of research and development. “Building upon emerging science related to fetal hemoglobin regulation, we intend to develop Sangamo’s novel gene-editing technology to create a single approach that has the potential to functionally cure both sickle cell disease and beta-thalassemia.”
The terms of the agreement detail that Sangamo will be responsible for all research and development through the first clinical proof of concept for beta-thalassemia and that both companies will perform R&D in the application for sickle cell disease. Biogen will then be responsible for global clinical development and marketing of the products that come to fruition.
Sangamo does retain the option to co-promote any licensed products in the U.S.
Logos courtesy of their respective owners.
